CD8A and acute lymphoblastic leukemia: Four weeks after treatment, EF further decreased in the PBS (−8 ± 7%), the CD8 (−6 ± 7%) and the ALL (−13 ± 10%) groups, but remained stable in the SPEC group (+1 ± 7%), (Fig. 2B–C).